---
title: "Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254997409.md"
description: "According to the Zhitong Finance APP, Asieris disclosed its semi-annual report for 2025, stating that the company achieved revenue of 130 million yuan during the reporting period, a year-on-year increase of 61.80%; the net profit attributable to the parent company was a loss of 162 million yuan; the net profit excluding non-recurring gains and losses was a loss of 177 million yuan; basic earnings per share were -0.29 yuan"
datetime: "2025-08-28T11:48:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254997409.md)
  - [en](https://longbridge.com/en/news/254997409.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254997409.md)
generator: "portal-rs"
---

# Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan

According to the Zhitong Finance APP, Asieris (688176.SH) disclosed its semi-annual report for 2025, reporting revenue of 130 million yuan, a year-on-year increase of 61.80%; a net loss attributable to shareholders of 162 million yuan; a net loss of 177 million yuan after deducting non-recurring items; and a basic earnings per share of -0.29 yuan

### Related Stocks

- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products](https://longbridge.com/en/news/297779978.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Gen Ilac Shares Shift to Call Auction After Circuit Breaker Halt](https://longbridge.com/en/news/297934526.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**